Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

Autor: Thomas Decker, Ulrike Söling, Antje Hahn, Christoph Maintz, Christian Martin Kurbacher, Ursula Vehling-Kaiser, Dagmar Sent, Peter Klare, Volker Hagen, Marco Chiabudini, Julia Falkenstein, Martin Indorf, Eva Runkel, Karin Potthoff

Publikováno v: BMC Cancer, Vol 20, Iss 1, Pp 1-12 (2020)

Abstract Background The objective of the IMPROVE study was patients’ preference for either endocrine-based therapy or combined chemo- and anti-angiogenic therapy in advanced HR-positive/HER2-negative breast cancer. Methods In this randomized, cross

Externí odkaz: https://doaj.org/article/0b607e2f74894218bc58a733d5c46416

Effectiveness and Tolerability of Nab-paclitaxel in Younger versus Elderly Patients With Metastatic HR-positive/HER2-negative Breast Cancer: Results From the Noninterventional, Prospective Study NABUCCO

Autor: Stephanie Dille, Richard A. Hansen, Johanna Harde, Karin Potthoff, Oliver Stötzer, Norbert Marschner, Ulrike Söling, Arnd Nusch

Publikováno v: Clinical Breast Cancer. 20:e315-e326

Background There are only scarce data on treatment of elderly patients with nab-paclitaxel for metastatic breast cancer, especially from the real-world setting. Here we present data from the noninterventional study NABUCCO with special focus on taxan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38fd85d112f803d5f2f28469709266c1
https://doi.org/10.1016/j.clbc.2019.11.003

Significance of Patient-Reported Outcomes for Metastatic Breast Cancer Patients

Autor: Larissa Elisabeth Hillebrand, Ulrike Söling, Norbert Marschner

Publikováno v: Oncology research and treatment. 45(7-8)

Background: Breast cancer is still the most common malignancy in women worldwide. Once metastasized, breast cancer treatment primarily aims at reducing symptom burden, thereby trying to maintain and improve a patient’s quality of life (QoL), delayi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::250fe326af87199bb7ed0180ef3c9134
https://pubmed.ncbi.nlm.nih.gov/34999590

Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

Autor: Antje Hahn, Julia Falkenstein, Dagmar Sent, Peter Klare, Christian M. Kurbacher, Ulrike Söling, Martin Indorf, Ursula Vehling-Kaiser, Volker Hagen, Marco Chiabudini, Karin Potthoff, Christoph Maintz, Eva Diana Runkel, Thomas Decker

Publikováno v: BMC Cancer, Vol 20, Iss 1, Pp 1-12 (2020)
BMC Cancer

Background The objective of the IMPROVE study was patients’ preference for either endocrine-based therapy or combined chemo- and anti-angiogenic therapy in advanced HR-positive/HER2-negative breast cancer. Methods In this randomized, cross-over pha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e37eaa1354845988cc5f4dc775c116af
https://doi.org/10.1186/s12885-020-06747-y

Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes

Autor: Peter Vandenberghe, Ulrike Söling, Ulrich Germing, Catharina Müller-Thomas, Uwe Platzbecker, Katayoon Shirneshan, Nicolaus Kröger, Corinna Strupp, Detlef Haase, Christina Ganster, Christel Müller, Gudrun Göhring, Julie Schanz, Mar Mallo, Michael Lübbert, Kiyoyuki Ogata, Claudia Haferlach, Francesc Solé, Barbara Hildebrandt, Katharina Götze, Tilman Steinmetz, Sophie Raynaud

Publikováno v: GENES CHROMOSOMES & CANCER
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

The karyotype is a strong independent prognostic factor in myelodysplastic syndromes (MDS). Since the implementation of the new comprehensive cytogenetic scoring system for MDS, chromosome 7 anomalies are no longer generally assigned to poor risk fea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aac49e9b935084c1151ce713a0a464c6
https://pubmed.ncbi.nlm.nih.gov/30994215